OPHTHALMIC DYE COMPOSITION AND METHOD FOR ADMINISTERING SAME
The present disclosure encompasses methods and compositions for staining ocular structures in ophthalmologic procedures. The compositions generally include a mydriatic compound and a dye. The compositions may additionally include a pain-relieving compound and a second mydriatic compound. Also provided herein is a method of delivering a pharmaceutical composition, which includes administering to an eye of a subject an ophthalmic pharmaceutical composition of the present disclosure.
1 . An ophthalmic pharmaceutical composition, the composition comprising:
a first mydriatic compound,
a first pain-relieving compound,
and a dye.
2 . The composition of claim 1 , wherein the first mydriatic compound comprises epinephrine, phenylephrine, tropicamide, atropine, brimonidine, cyclopentolate, homatropine, 4-hydroxyamphetamine, or scopolamine, or pharmaceutically acceptable salts thereof.
3 . The composition of claim 1 wherein the first mydriatic compound has a concentration from about 0.01% (w/v) to about 2% (w/v).
4 . The composition of claim 1 , wherein the first pain-relieving compound comprises lidocaine, proparacaine, tetracaine, dexamethasone, fluorometholone, fluocinolone, loteprednol, loteprednol, difluprednate, triamcinolone, prednisolone, medrysone, or rimexolone, or pharmaceutically acceptable salts thereof.
5 . The composition of claim 1 , wherein the dye comprises trypan blue, fluorescein, lissamine green, rose Bengal, indocyanine green, triamcinolone acetonide, bromophenol blue, patent blue, brilliant blue G (acid blue), or a combination thereof.
6 . The composition of claim 1 wherein the first pain-relieving compound has a concentration from about 0.5% (w/v) to about 2% (w/v).
7 . The composition of claim 1 wherein the first mydriatic compound comprises epinephrine and the first pain-relieving compound comprises lidocaine.
8 . The composition of claim 7 wherein the epinephrine has a concentration from about 0.01% (w/v) to about 0.05% (w/v).
9 . The composition of claim 7 wherein the lidocaine has a concentration from about 0.5% (w/v) to about 2% (w/v).
10 . The composition of claim 1 wherein the first mydriatic compound is phenylephrine and the first pain-relieving compound is lidocaine.
11 . The composition of claim 1 wherein the first mydriatic compound is tropicamide.
12 . The composition of claim 11 wherein the tropicamide has a concentration from about 0.1% (w/v) to about 0.5% (w/v).
13 . The composition of claim 1 further comprising a second mydriatic compound and a second pain-relieving compound.
14 . The composition of claim 13 , wherein the second mydriatic compound comprises epinephrine, phenylephrine, tropicamide, atropine, brimonidine, cyclopentolate, homatropine, 4-hydroxyamphetamine, or scopolamine, or pharmaceutically acceptable salts thereof.
15 . The composition of claim 13 , wherein the second pain-relieving compound comprises lidocaine, proparacaine, tetracaine, dexamethasone, fluorometholone, fluocinolone, loteprednol, loteprednol, difluprednate, triamcinolone, prednisolone, medrysone, or rimexolone, or pharmaceutically acceptable salts thereof.
16 . The composition of claim 13 wherein the second pain-relieving compound is a non-steroidal anti-inflammatory drug.
17 . The composition of claim 13 wherein the first mydriatic compound is tropicamide, the second mydriatic compound is phenylephrine, the first pain-relieving compound is lidocaine, and the second pain-relieving compound is diclofenac.
18 . The composition of claim 17 wherein the tropicamide has a concentration from about 0.1% (w/v) to about 0.5% (w/v).
19 . The composition of claim 17 wherein the phenylephrine has a concentration from about 0.01% (w/v) to about 2% (w/v).
20 . The composition of claim 17 wherein the lidocaine has a concentration from about 0.5% (w/v) to about 2% (w/v).
21 . The composition of claim 17 wherein the diclofenac has a concentration from about 0.01% (w/v) to about 0.5% (w/v).
22 . The composition of claim 16 wherein the concentration of the non-steroidal anti-inflammatory drug is from about 0.1% (w/v) to about 0.5% (w/v).
23 . The composition of claim 1 wherein the dye has a concentration from about 0.01% (w/v) to about 0.25% (w/v).
24 . The composition of claim 1 , wherein the composition is essentially free of preservatives and sulfites.
25 . A method of delivering an ophthalmic pharmaceutical composition, the method comprising administering to an eye of a subject an ophthalmic pharmaceutical composition claim 1 .